iBio, Inc. (NYSEAMERICAN:IBIO) Sees Large Growth in Short Interest

iBio, Inc. (NYSEAMERICAN:IBIO – Get Rating) was the target of a large growth in short interest in the month of December. As of December 30th, there was short interest totalling 1,080,000 shares, a growth of 18.2% from the December 15th total of 913,500 shares. Based on an average daily trading volume, of 445,400 shares, the short-interest ratio is currently 2.4 days. Currently, 10.5% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald lowered shares of iBio from an “overweight” rating to a “neutral” rating in a report on Thursday, October 6th.

Institutional Trading of iBio

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in iBio by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 11,884,917 shares of the biotechnology company’s stock valued at $2,024,000 after purchasing an additional 829,836 shares during the last quarter. BlackRock Inc. raised its position in shares of iBio by 71.7% during the 3rd quarter. BlackRock Inc. now owns 6,799,636 shares of the biotechnology company’s stock worth $1,158,000 after buying an additional 2,838,918 shares in the last quarter. Millennium Management LLC bought a new stake in shares of iBio during the 2nd quarter worth about $1,219,000. Renaissance Technologies LLC raised its position in shares of iBio by 11.9% during the 3rd quarter. Renaissance Technologies LLC now owns 1,287,827 shares of the biotechnology company’s stock worth $219,000 after buying an additional 136,450 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of iBio by 10.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 586,227 shares of the biotechnology company’s stock worth $252,000 after buying an additional 54,084 shares in the last quarter.

iBio Stock Performance

Shares of NYSEAMERICAN:IBIO opened at $0.70 on Friday. The stock has a market capitalization of $6.30 million, a P/E ratio of -0.19 and a beta of -3.36. iBio has a fifty-two week low of $0.36 and a fifty-two week high of $16.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.97 and a current ratio of 1.97.

iBio Company Profile

(Get Rating)

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.